Patiromer to Enable Spironolactone in Patients with Resistant Hypertension and CKD (AMBER): Results in the Prespecified Subgroup with Diabetes

Affiliations

• ¹ Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.
• ² Inserm 1433 CIC-P CHRU de Nancy, Inserm U1116 and FCRIN INI-CRCT,, University of Lorraine, Nancy, France.
• ³ Clinical Development, Vifor Pharma, Inc, Redwood City, California.
• ⁴ Medical Affairs, Vifor Pharma, Inc., Redwood City, California.
• ⁵ Biostatistics, Vifor Pharma, Inc., Redwood City, California.
• ⁶ Department of Medicine, Institute of Cardiovascular Sciences, University College London (UCL) and National Institute for Health Research (NIHR) UCL/UCL Hospitals Biomedical Research Centre, London, United Kingdom.
• ⁷ Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut.